ID Week

In the Opening Plenary of IDWeek 2019, 2 bright lights in infectious disease research spoke on the sea-change brought by genomics to biomedicine and the response to infectious disease outbreaks.

A total of 168,420 dental visits included antibiotic prophylaxis, 136,177 (80%) of which were deemed unnecessary.

Adverse events led to premature discontinuation in 14% (21) of ISA patients and 53% (85) of patients receiving VOR prophylaxis.

A presentation at IDWeek 2019 gives hope for the rapid identification and isolation of extensively drug-resistant organisms.

Investigators observed no moderate, severe, cumulative, or dose-limiting adverse events leading to discontinuation, and ACX-362E was generally well-tolerated at all dose levels.

In a new study, a team of investigators set out to determine if oritavancin use can reduce the sequelae from ABSSSI treatment failures, while also preventing infection recurrences and improving patient outcomes.

An oral abstract session on public health covers the full gamut of new outbreaks, challenges from around the world.

Investigators assessed rates of all-cause mortality at Day 14 for Cefiderocol and meropenem in patients with nosocomial gram-negative pneumonia.

When it came to infection prevention measures, 5 of the 9 Orange County facilities with C auris displayed hand hygiene adherence < 50%, 3 had limited access to alcohol-based hand rubs, and < 60% of assessed high-touch surfaces were clean.

As September draws to a close, the Contagion® editorial team is recapping the trends and top infectious disease news of the month.

The Contagion® editorial staff will be providing exclusive written and video coverage from IDWeek 2019.

Emily Ricotta, PhD, ScM, highlights the increase in non-albicans candidiasis, which tends to be more antibiotic resistan,t in both bloodstream and sterile-site infections.

Melvin Weinstein MD, discusses the emerging technologies that will advance the field of blood culture testing.

Julie Ann Justo, PharmD, discusses the myths associated with penicillin allergies and why it is important to determine a patient's true penicillin allergy-status.

Kenneth Sherman, MD, discusses hepatitis B infections in immunocompromised patients and what clinicians should expect to see in the future for hepatitis B treatment.

As clinicians and health care executives work to strike a balance between reducing costs and improving clinical outcomes, the importance of sepsis identification and treatment cannot be underscored enough, and starts with evaluating current practices for infection management.

Brad Spellberg, MD, highlights research that indicate shorter courses of therapy are safer and as effective as longer ones, as well as the importance of randomized controlled trials.

Highest amounts of Toxocara egg contamination were in areas that could contain food droppings or animal waste.

Data from a pooled analysis of the REVIVE-1 and 2 studies found iclaprim to be non-inferior to vancomycin based on earl clinical response in patients with wound infections.

The phase 3 CAPSTONE-2 trial shows treatment with baloxavir marboxil significantly reduced the time to improvement of flu symptoms compared with placebo.

ID Week 2018 was held October 2-7, 2018, in San Francisco, California. The conference featured results of new studies on a variety of infectious disease topics as well as advancements being made in the field. Here are 5 key takeaways from the meeting.

A study of more than 500 outpatient clinics reveals a new view of antibiotic overprescribing practices in the United States.

We sat down with several infectious disease experts to learn more about their research and asked them to share what they’re taking home from ID Week 2018.

Approximately 10% of US patients report having an allergic relation to penicillin, yet only 1% of the population are truly allergic.

Cristen Whittaker, PharmD, explains the findings of an analysis that compared length of stay, readmission, and costs in patients with ABSSSIs who received oritavancin or vancomycin.

An eVLP cytomegalovirus (CMV) vaccine was found to be safe and immunogenic at very low doses in healthy seronegative adults.

Jason Pogue, PharmD, BCPS-AQID, discusses the need for real-world data to support Ceftolozane/tazobactam and shares the findings of his comparative study on using the regimen to treat MDR/XDR Pseudomonas aeruginosa.

Taking a closer look at the infectious disease risks posed by transplantation and what the future might have in store as the scope of transplantation expands.

Keith Kaye, MD, presented the analysis of the RESTORE-IMI 1 phase 3 trial which evaluated imipenem/cilastatin/relebactam versus imipenem/cilastatin plus colistin.

Kenneth E. Sherman, MD discusses the zoonotic hepatitis E virus and about the first reported case of rat-to-human transmission.